Herpes Zoster Post-COVID-19 Vaccination in Young Adults (Under 35) Case Series

Sophie Guénin MSc\textsuperscript{1,2}, Emily Elbogen PA\textsuperscript{2}, Mindy Kresch BS\textsuperscript{2}, Mark Lebwohl MD\textsuperscript{2}

\textsuperscript{1} New York Medical College, Valhalla, NY
\textsuperscript{2} Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY

**ABSTRACT**

An increasing number of reports have indicated correlation between COVID-19 vaccination and herpes zoster. While these outbreaks may be largely coincidental, the correlation warrants further investigation. Herein, we present 4 cases of herpes zoster in young healthy adults with no known risk factors for varicella virus reactivation. To date, most zoster outbreaks have been in patients above 60 years old. Thus, we believe that these cases point to a need for increased research on the topic.

**INTRODUCTION**

Within the last six months, there have been growing reports of herpes zoster (HZ) or shingles after vaccination with both Pfizer BNT162b2 and Moderna mRNA-1273 vaccines\textsuperscript{1,2,3,4,5}. HZ is caused by the varicella-zoster virus (VZV) that typically infects in childhood and remains dormant in ganglionic neurons, indefinitely. VZV is a human-specific herpesvirus that targets neurons, T lymphocytes, and epithelial cells\textsuperscript{6}. Primary infection causes chickenpox and reactivation, later in life, causes HZ\textsuperscript{6}. Reactivation of VZV commonly produces a characteristic painful, erythematous, vesicular rash in a dermatomal distribution\textsuperscript{6}. The lesion is often followed by post-herpetic neuralgia, a type of neuropathic pain lasting months after rash resolution\textsuperscript{6}. Less commonly, HZ may also lead to life-threatening conditions such as meningoencephalitis, vasculopathies, and infection\textsuperscript{6}.

A systematic review, of all reported cases to date, demonstrated that the mean age of COVID-19-vaccine associated HZ was 62 years of age, with the majority of patients being over the age of 60\textsuperscript{7}. In addition, HZ was reported more frequently with first dose vaccinations and with a delay of 3 to 9 days post-injection\textsuperscript{6}. While these associations may be largely coincidental and causality remains to be demonstrated, we present four cases of HZ in healthy, young adults under the age of 35 who received either the BNT162b2 or mRNA-1273 vaccine. These cases illustrate that HZ does not only affect those over the age of 60 post-vaccination, but also those with no known risk factors. However, it is very important to emphasize that these cases do not establish association. Our goal is to call for closer investigation given the anecdotal increase in HZ cases seen in our vaccinated patients.

**CASE SERIES**
Case 1. A healthy 27-year-old female with polycystic ovarian syndrome (PCOS), received her second dose of BNT162b2 vaccine in her left arm. Thirty days later, a group of itchy, painful erythematous papules and vesicles erupted on the right shoulder in the C6 dermatomal distribution (Figure 1). There was history of past varicella infection as a child, but no history of previous HZ. Seven days of valacyclovir was administered and resulted in complete resolution of lesion three weeks later.

Figure 1. Clustered, erythematous vesicles on right shoulder

Case 2. A healthy 20-year-old male with a past medical history of asthma presented with HZ six days after receiving his second injection of the BNT162b2 vaccine in his left arm. The lesion appeared in the T10 dermatomal distribution on the left abdomen (Figure 2). There was history of past varicella immunization during childhood. The patient’s lesion resolved after 10 days of valacyclovir treatment.

Figure 2. Herpes zoster in T10 dermatomal distribution in 20-year-old male

Case 3. A healthy 32-year-old female with a history of nephrolithiasis presented with HZ 28 days post-vaccination with second dose of the mRNA-1273 vaccine in her left arm. The lesion was located over the right breast in a T4 dermatomal distribution. There was history of childhood infection of varicella, but no history of prior HZ. The patient’s lesion resolved after 10 days of valacyclovir treatment.

Case 4. A healthy 27-year-old female with no significant past medical history presented with HZ 39 days after second dose of the mRNA-1273 vaccine in her right arm. The lesion was located on her left arm in a T1 distribution. There was a history of childhood infection of varicella, but no history of prior HZ. The patient’s lesion resolved after 10 days of valacyclovir treatment.

DISCUSSION

Our case series demonstrates a potential correlation between COVID-19 vaccination and HZ in individuals with no reactivation risk factors. In three of the presented cases, reactivation of the virus occurred about a month after injection compared to the 3-to-9-day delay previously reported7. Varicella reactivation presented 6 days subsequent to COVID-19 vaccination in a varicella immunized patient, indicating likely reactivation of the Oka strain varicella zoster virus (OkaVZV). In addition, all four HZ cases were associated with second dose vaccination unlike previous reports demonstrating association more frequently with first-doses7. These differences may indicate a different reactivation mechanism between the two groups or support mere coincidence.
The precise mechanism leading to maintenance of VZV latency and reactivation remains highly controversial and poorly understood. However, it is largely believed that HZ occurs in response to a decline in cell-mediated immunity as a result of aging or immunocompromised states.

BNT162b1 and mRNA-1273 vaccines direct synthesis of the SARS-COV-2 spike (S) protein, which is recognized by antigen-presenting cells and elicits a predominantly type 1 helper T (Th1) cell response. The mRNA-1273 vaccine was shown to elicit strong release of TNF-α, IL-2, and INF-γ in individuals aged 56 to 70 years. Cytokine levels were highest after about 1-month post-injection, which would coincide with the HZ cases in three of our young adults. The increase in cytokine expression and Th1 cell response may effectively disrupt immune cell homeostasis leading to VZV evasion of the innate immune system and subsequent reactivation. However, this would not be unique to the COVID-19 vaccines as HZ has also been reported after hepatitis A, influenza, rabies, and Japanese encephalitis vaccination.

Others have hypothesized that the transient lymphopenia seen in 45.5% of individuals receiving BNT162b1 may explain HZ incidence. Apparent lymphopenia may be caused by the surge in type I interferons that regulate lymphocyte extravasation from circulation. Interestingly, biopsied HZ lesions are depleted of Langerhans cells that help modulate the skin’s innate immunity. Thus, while functionally, the immune system is intact, lymphocytes may not be able to localize to the skin and maintain VZV latency. Some other contributing factors that may explain HZ post-vaccination may include pandemic or vaccine-related emotional and physical stress, which could lead to a spike in cortisol, a known immunosuppressant.

Lastly, we must also acknowledge the variety of confounding factors in reported HZ cases during the pandemic. The pandemic and constant focus on health may have led to some patients having a lower threshold for calling their physicians leading to an increase in reported HZ cases. At the same time, other patients may have chosen to avoid healthcare spaces for fear of COVID-19 infection leading to possibly underreported HZ cases.

CONCLUSION

Taken together, these reports of HZ subsequent to BNT162b1 and mRNA-1273 vaccination warrant further studies in controlled environments to either establish coincidence or association. These future studies will be especially important in counseling patients prior to COVID-19 booster vaccines.

Conflict of Interest Disclosures: Mark Lebwohl is an employee of Mount Sinai and receives research funds from: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Dermavant Sciences, Eli Lilly, Incyte, Janssen Research & Development, LLC, Ortho Dermatologics, Regeneron, and UCB, Inc., and is a consultant for Aditum Bio, Almirall, AltruBio Inc., AnaptysBio, Arcutis, Inc., Arista Therapeutics, Arrive Technologies, Avotres Therapeutics, BiomX, Boehringer-Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Dr. Reddy’s Laboratories, Evelo Biosciences, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences, Foundation for Research and Education in Dermatology, Helsinn Therapeutics, Hexima Ltd., LEO Pharma, Meiji Seika Pharma, Mindera, Pfizer, Seagen, and Verrica. Authors Guénin, Kresch, and Elbogen have no conflicts of interest to declare.

Funding: None

Corresponding Author:
Sophie Guénin, MSc
Department of Dermatology
Icahn School of Medicine at Mount Sinai Hospital
5 East 98th Street, 5th Floor

(c) 2022 THE AUTHORS. Published by the National Society for Cutaneous Medicine.
References:
1. Lee, C., Cotter, D., Basa, J., & Greenberg, H. L. (2021). Post COVID-19 Vaccine Related Shingles Cases seen at the Las Vegas Dermatology Clinic and sent to us via Social Media. Journal of Cosmetic Dermatology.

2. Channa, L., Torre, K., & Rothe, M. (2021). Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination. JAAD Case Reports, 15, 60-61.

3. Eid, E., Abdullah, L., Kurban, M., & Abbas, O. (2021). Herpes zoster emergence following mRNA COVID-19 vaccine. Journal of Medical Virology.

4. Bostan, E., & Yalici-Armagan, B. (2021). Herpes zoster following inactivated COVID-19 vaccine: a coexistence or coincidence?. Journal of Cosmetic Dermatology.

5. Lladó, I., Fernández-Bernáldez, A., & Rodríguez-Jiménez, P. (2021). Varicella zoster virus reactivation and mRNA vaccines as a trigger. JAAD Case Reports, 15, 62-63.

6. Gershon, A. A., Breuer, J., Cohen, J. I., Cohrs, R. J., Gershon, M. D., Gilden, D., ... & Yamanishi, K. (2015). Varicella zoster virus infection. Nature reviews Disease primers, 1(1), 1-18.

7. Katsikas Triantafyllidis, K., Giannos, P., Mian, I. T., Kyrtonis, G., & Kechagias, K. S. (2021). Varicella Zoster Virus Reactivation Following COVID-19 Vaccination: A Systematic Review of Case Reports. Vaccines, 9(9), 1013.

8. Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., ... & Beigel, J. H. (2020). Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. New England Journal of Medicine, 383(25), 2427-2438.

9. Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., ... & Türeci, Ö. (2020). COVID-19 vaccine BNT162b1 elicits human antibody and TH 1 T cell responses. Nature, 586(7830), 594-599.

10. Walter, R., Hartmann, K., Fleisch, F., Reinhart, W. H., & Kuhn, M. (1999). Reactivation of herpesvirus infections after vaccinations?. The Lancet, 353(9155), 810.

11. Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., ... & Jansen, K. U. (2020). Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature, 586(7830), 589-593.

12. Kamphuis, E., Junt, T., Waibler, Z., Forster, R., & Kalinke, U. (2006). Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood, 108(10), 3253-3261.

13. Laing, K. J., Ouwendijk, W. J., Koelle, D. M., & Verjans, G. M. (2018). Immunobiology of varicella-zoster virus infection. The Journal of infectious diseases, 218(suppl_2), S68-S74.